- Home
- NRXS vs INBS Comparison
NRXS vs INBS Comparison
Compare NRXS & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- INBS
- Stock Information
- Founded
- NRXS 2011
- INBS 2016
- Country
- NRXS United States
- INBS United States
- Employees
- NRXS N/A
- INBS N/A
- Industry
- NRXS
- INBS Medical Specialities
- Sector
- NRXS
- INBS Health Care
- Exchange
- NRXS Nasdaq
- INBS Nasdaq
- Market Cap
- NRXS 13.0M
- INBS 11.7M
- IPO Year
- NRXS 2023
- INBS N/A
- Fundamental
- Price
- NRXS $2.41
- INBS $1.47
- Analyst Decision
- NRXS Strong Buy
- INBS
- Analyst Count
- NRXS 1
- INBS 0
- Target Price
- NRXS $7.00
- INBS N/A
- AVG Volume (30 Days)
- NRXS 55.7K
- INBS 188.5K
- Earning Date
- NRXS 08-12-2025
- INBS 08-15-2025
- Dividend Yield
- NRXS N/A
- INBS N/A
- EPS Growth
- NRXS N/A
- INBS N/A
- EPS
- NRXS N/A
- INBS N/A
- Revenue
- NRXS $3,217,531.00
- INBS $3,052,532.00
- Revenue This Year
- NRXS $73.05
- INBS $280.88
- Revenue Next Year
- NRXS $130.42
- INBS $126.26
- P/E Ratio
- NRXS N/A
- INBS N/A
- Revenue Growth
- NRXS 41.93
- INBS N/A
- 52 Week Low
- NRXS $1.33
- INBS $1.00
- 52 Week High
- NRXS $6.20
- INBS $3.00
- Technical
- Relative Strength Index (RSI)
- NRXS 42.66
- INBS 41.02
- Support Level
- NRXS $2.26
- INBS $1.42
- Resistance Level
- NRXS $2.57
- INBS $1.53
- Average True Range (ATR)
- NRXS 0.14
- INBS 0.09
- MACD
- NRXS -0.02
- INBS -0.01
- Stochastic Oscillator
- NRXS 37.94
- INBS 25.00
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).